Trevi Therapeutics, Inc., a New Haven, CT-based drug development company, has closed a $10m Series A financing.
Backers include TPG Biotech, which had previously made a seed investment in the company to conduct pre-clinical testing, regulatory activities, initial clinical planning and the prosecution of its intellectual property.
Trevi now intends to use the capital to advance the clinical development of T111, an oral extended release opioid with an agonist/antagonist mechanism of action, in the lead indication of uremic pruritus (a severe chronic itching condition).
In conjunction with the funding, Eran Nadav, Ph.D. and Cayce Denton, from TPG Biotech, will join the company’s founders Dr. Thomas Sciascia and Jennifer Good, President and Chief Executive Officer, on the board of directors.
FinSMEs
18/12/2012